Catatonia as a result of autoimmune conditions offers new therapeutic opportunities for patients that child and adolescent psychiatrists should consider. However, the diagnosis is sometimes challenging when an autoimmune signature is not identified.
Methods:
In this study, we aim to summarize seven cases from a 20-year series of 84 youths with catatonia, including three cases that represented a diagnostic challenge because of the absence of positive autoimmune testing.
Results:
Immunosuppressive/modulatory treatment improved catatonic and psychotic features in all cases.
Conclusion:
To facilitate treatment decision-making, we propose a causality assessment score and a treatment algorithm, which may help clinicians consider whether an autoimmune condition is associated with catatonia.
Get full access to this article
View all access options for this article.
References
1.
AgrawalS, VincentA, JacobsonL, MilfordD, GuptaR, WassmerE: Successful treatment of antiN-methyl-d-aspartate receptor limbic encephalitis in a 22-month old child with plasmapheresis and pharmacological immunomodulation. Arch Dis Child, 95:312, 2010.
ArmangueT, TitulaerMJ, MalagaI, BatallerL, GabilondoI, GrausF, DalmauJ: Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr, 162:850–856.e2, 2013.
4.
BegaudB, EvreuxJC, JouglardJ, LagierG: Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie, 40:111–118, 1985.
5.
BushG, FinkM, PetridesG, DowlingF, FrancisA: Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand, 93:129–136, 1996.
6.
ByrneS, WalshC, HacohenY, MuscalE, JankovicJ, StoccoA, DaleRC, VincentA, LimM, KingM: Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm. 2:e130, 2015.
7.
ChangK, FrankovichJ, CooperstockM, CunninghamMW, LatimerME, MurphyTK, PasternackM, ThienemannM, WilliamsK, WalterJ, SwedoSE: Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): Recommendations from the 2013 PANS consensus conference. J Child Adolesc Psychopharmacol, 25:3–13, 2015.
8.
CohenD, NicolasJD, FlamentMF, PerisseD, DubosPF, BonnotO, SperanzaM, GraindorgeC, TordjmanS, MazetP: Clinical relevance of chronic catatonic schizophrenia in children and adolescents: Evidence from a prospective naturalistic study. Schizophr Res, 76:301–308, 2005.
9.
ConsoliA, BenmiloudM, WachtelL, DhosscheD, CohenD, BonnotO: Electroconvulsive therapy in adolescents with the catatonia syndrome: Efficacy and ethics. J ECT, 26:259–265, 2010.
10.
ConsoliA, RaffinM, LaurentC, BodeauN, CampionD, AmouraZ, SedelF, An-GourfinkelI, BonnotO, CohenD: Medical and developmental risk factors of catatonia in children and adolescents: A prospective case-control study. Schizophr Res, 137:151–158, 2012.
11.
ConsoliA, RonenK, An-GourfinkelI, BarbeauM, MarraD, Costedoat-ChalumeauN, MontefioreD, MaksudP, BonnotO, DidelotA, AmouraZ, VidailhetM, CohenD: Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: Case report. Child Adolesc Psychiatry Ment Health, 5:15, 2011.
12.
CornicF, ConsoliA, TanguyML, BonnotO, PerisseD, TordjmanS, LaurentC, CohenD: Association of adolescent catatonia with increased mortality and morbidity: Evidence from a prospective follow-up study. Schizophr Res, 113:233–240, 2009.
13.
CoxCJ, ZuccoloAJ, EdwardsEV, Mascaro-BlancoA, AlvarezK, StonerJ, ChangK, CunninghamMW: Antineuronal antibodies in a heterogeneous group of youth and young adults with tics and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol, 25:76–85, 2015.
14.
DalmauJ, GleichmanAJ, HughesEG, RossiJE, PengX, LaiM, DessainSK, RosenfeldMR, Balice-GordonR, LynchDR: Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol, 7:1091–1098, 2008.
15.
DalmauJ, LancasterE, Martinez-HernandezE, RosenfeldMR, Balice-GordonR: Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol, 10:63–74, 2011.
16.
DimitriD, JehelL, DurrA, Levy-SoussanM, AndreuxV, LaplancheJL, FossatiP, CohenD: Fatal familial insomnia presenting as psychosis in an 18-year-old man. Neurology, 67:363–364, 2006.
17.
EliaJ, DellML, FriedmanDF, ZimmermanRA, BalamuthN, AhmedAA, PatiS: PANDAS with catatonia: A case report: Therapeutic response to lorazepam and plasmapheresis. J Am Acad Child Adolesc Psychiatry, 44:1145–1150, 2005.
FloranceNR, DavisRL, LamC, SzperkaC, ZhouL, AhmadS, CampenCJ, MossH, PeterN, GleichmanAJ, GlaserCA, LynchDR, RosenfeldMR, DalmauJ: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol, 66:11–18, 2009.
20.
FrankovichJ, ThienemannM, RanaS, ChangK: Five youth with pediatric acute-onset neuropsychiatric syndrome of differing etiologies. J Child Adolesc Psychopharmacol, 25:31–37, 2015.
21.
Gresa-ArribasN, TitulaerMJ, TorrentsA, AguilarE, McCrackenL, LeypoldtF, GleichmanAJ, Balice-GordonR, RosenfeldMR, LynchD, GrausF, DalmauJ: Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: A retrospective study. Lancet Neurol, 13:167–177, 2014.
22.
HacohenY, WrightS, WatersP, AgrawalS, CarrL, CrossH, De SousaC, DevileC, FallonP, GuptaR, HedderlyT, HughesE, KerrT, LascellesK, LinJP, PhilipS, PohlK, PrabahkarP, SmithM, WilliamsR, ClarkeA, HemingwayC, WassmerE, VincentA, LimMJ: Paediatric autoimmune encephalopathies: Clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry, 84:748–755, 2013.
23.
HonnoratJ, DidelotA, KarantoniE, VilleD, DucrayF, LambertL, DeivaK, GarciaM, PichitP, CavillonG, RogemondV, DeLattreJY, TardieuM: Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology, 80:2226–2232, 2013.
24.
IshiuraH, MatsudaS, HigashiharaM, HasegawaM, HidaA, HanajimaR, YamamotoT, ShimizuJ, DalmauJ, TsujiS: Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology, 71:1921–1923, 2008.
25.
KashyapeP, TaylorE, NgJ, KrishnakumarD, KirkhamF, WhitneyA: Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: The need for early aggressive immunotherapy in tumour negative paediatric patients. Eur J Paediatr Neurol, 16:74–78, 2012.
26.
KovacevicM, GrantP, SwedoSE: Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Child Adolesc Psychopharmacol, 25:65–69, 2015.
27.
LahutteB, CornicF, BonnotO, ConsoliA, An-GourfinkelI, AmouraZ, SedelF, CohenD: Multidisciplinary approach of organic catatonia in children and adolescents may improve treatment decision making. Prog Neuropsychopharmacol Biol Psychiatry, 32:1393–1398, 2008.
28.
LanhamJG, BrownMM, HughesGR: Cerebral systemic lupus erythematosus presenting with catatonia. Postgrad Med J, 61:329–330, 1985.
29.
LatimerME, L'EtoileN, SeidlitzJ, SwedoSE: Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections. J Child Adolesc Psychopharmacol, 25:70–75, 2015.
MarraD, AmouraZ, SoussanN, HarocheJ, ConsoliA, Ghillami-DalbinP, DiemertMC, MussetL, PietteJC, CohenD: Plasma exchange in patients with stuporous catatonia and systemic lupus erythematosus. Psychother Psychosom, 77:195–196, 2008.
32.
NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, JanecekE, DomecqC, GreenblattDJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245, 1981.
33.
NorthoffG, KochA, WenkeJ, EckertJ, BfkerH, PflugB, BogertsB: Catatonia as a psychomotor syndrome: A rating scale and extrapyramidal motor symptoms. Mov Disord, 14:404–416, 1990.
34.
PerisseD, AmouraZ, CohenD, SaintignyP, MekhloufiF, MazetP, PietteJC: Case study: Effectiveness of plasma exchange in an adolescent with systemic lupus erythematosus and catatonia. J Am Acad Child Adolesc Psychiatry, 42:497–499, 2003.
35.
RosebushPI, HildebrandAM, FurlongBG, MazurekMF: Catatonic syndrome in a general psychiatric population: Frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry, 51:357–362, 1990.
36.
SchimmelM, BienCG, VincentA, SchenkW, PenzienJ: Successful treatment of anti-N-methyl-D-aspartate receptor encephalitis presenting with catatonia. Arch Dis Child, 94:314–316, 2009.
37.
TakaokaK, TakataT: Catatonia in childhood and adolescence. Psychiatry Clin Neurosci, 57:129–137, 2003.
38.
TitulaerMJ, McCrackenL, GabilondoI: Clinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis. Neurology, 78 (Suppl. PL01.001), 2012.
39.
TitulaerMJ, McCrackenL, GabilondoI, ArmangueT, GlaserC, IizukaT, HonigLS, BenselerSM, KawachiI, Martinez-HernandezE, AguilarE, Gresa-ArribasN, Ryan-FloranceN, TorrentsA, SaizA, RosenfeldMR, Balice-GordonR, GrausF, DalmauJ: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol, 12:157–165, 2013.
40.
WilsonJE, ShusterJ, FuchsC: Anti-NMDA receptor encephalitis in a 14-year-old female presenting as malignant Catatonia: Medical and psychiatric approach to treatment. Psychosomatics, 54:585–589, 2013.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
